Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy

Sensorion selects one hearing loss program, axes another; Novartis hits biomarker endpoint for muscular dystrophy drug; J&J's antibody succeeds in blood disorder

Raccontata daendpoints.news